Background: Irisin is a new myokin and adipokine related to human obesity and insulin resistance status.
Aim: To assess serum irisin level as well as to investigate whether serum irisin is related to glycemic indicators, and micro and macrovascular complications in patients with T2DM.
Methods: The study included 60 T2DM patients and 30 healthy controls. Anthropometric measures, neurological assessment and fundus examination were done to all patients. Correlations of serum irisin and blood glucose, glycosylated hemoglobin (HbA1C), urinary albumin, estimated glomerular filtration rat (eGFR), C-reactive protein (CRP), and carotid intima media thickness (CIMT) were analyzed using Spearmans correlation coefficient.
Results: There was no significant difference of irisin level between T2DM patients and healthy controls (0.18±0.10 vs. 0.16±0.05 ng/ml, P=0.940). In diabetic patients, there was negative correlation between irisin level and duration of diabetes (r=−0.302, P=0.023), BMI (r=−0.663, P <0.001), HbA1C (r=−0.528, P<0.001), urinary albumin (r=−0.439, P <0.001), CRP (r=−0.692, P<0.001), and CIMT (r=−0.807, P<0.001). Levels of irisin were significantly lower in patients with peripheral diabetic neuropathy (PDN) compared to those without PDN (0.11±0.05 vs. 0.22±0.11 ng/ml, P< 0.001). Levels of irisin was not significantly different between patients with diabetic retinopathy and those with normal fundi.
Conclusions: Serum irisin levels were not different between T2DM subjects and controls. In T2DM patients, negative correlations between irisin and HbA1C, urinary albumin, CIMT were found. Patients with diabetic neuropathy had lower irisin levels.
Keywords: Type 2 diabetes, irisin, carotid intima media thickness, nephropathy, neuropathy
18 - 21 May 2019
European Society of Endocrinology